Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development

Yazhuo Huang; Sijie Fang; Shuo Zhang; Huifang Zhou

doi:10.4103/tjo.tjo_18_20

Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development

Taiwan J Ophthalmol. 2020 Jul 17;10(3):174-180. doi: 10.4103/tjo.tjo_18_20. eCollection 2020 Jul-Sep.

Authors

Yazhuo Huang^{1

2}, Sijie Fang^{1

2}, Shuo Zhang^{1

2}, Huifang Zhou^{1

2}

Affiliations

¹ Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
² Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China.

Abstract

Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of toxic diffuse goiter (Graves' disease), also known as Graves' ophthalmopathy/orbitopathy. As an organ-specific autoimmune disease, the pathogenesis of TAO is still unclear. In recent years, great progress has been made in revealing the mechanism of TAO. Various biological and immunosuppressive agents have emerged in an endless stream, showing encouraging results. Strengthening the basic research, establishing ideal animal models, deeply understanding the pathogenesis, and developing novel targeted drugs are of great significance to guide the clinical diagnosis and management of TAO and improve the prognosis of patients.

Keywords: Immunotherapy; new drug development; thyroid-associated ophthalmopathy.

Publication types

Review